CD58 and neoplasm: The absence of CD58 BiTE or the loss of interaction between CD2 and CD58 results in diminished TCE-β-mediated cytotoxicity, T cells activation, and anti-tumor efficacy, constituting a primary mechanism of BiTE resistance.